Alnylam has teamed up with Diperna to develop RNAi therapy for rare liver disease

, Alnylam and Diperna jointly announced that they will cooperate in the development of a treatment for liver disease (α-1) related to α-1 antitrinase (A1AT) deficiency in its ALN-AAT02 and DCR-A1AT. In addition, the two companies have cross-licensed their respective intellectual property rights for their research programs for the treatment of primary high herbic acid uremia (PH).ALN-AAT02 and DCR-A1AT are sethopaedic injection RNAi therapies targeted at A1AT for the treatment of liver disease associated with A1AT deficiency. AlN-AAT02 was developed using Alnylam's ESC-GalNAc conjugate technology, which enables higher selectivity and a wider therapeutic index. DCR-A1AT uses Dicerna's GalXCTM technology to optimize the activity of the RNAi pathway while enabling off-skin delivery, making it more specific and efficient to operate.Under the terms of the agreement, Dicerna will lead the global clinical development of DCR-A1AT and ALN-AAT02 and its commercialization activities in the United States. Alnylam retains the right to commercialize outside the United States after completing Phase 3 trials. If Alnylam relinquies its commercial options, Dicerna reserves the right to commercialize selected drugs worldwide in exchange for potential milestone payments due to Alnylam and future sales share of the drugs developed.In the cross-licensing agreement, Alnylam and Diperna granted non-exclusive cross-licensing of each other's intellectual property rights related to the PH Therapeutics Research Program to ensure that both parties are free to develop and commercialize their respective candidate products, and provided that Allenylam pays Dierna a share based on lumasiran's global net sales and a share of Diderna's payments to Allenilam based on nedirosan's global net sales.“ We are excited to bring together two leading RNAi therapeutic companies to develop potentially transformative drugs to treat rare diseases with severely untreated needs,α" said Dr. John Maraganore, Chief Executive Officer of Alnylam. " (
medicine Mingkangde
)